Physician profile
Jillian M Kinzel
NPI 1861769572
$5,131.87
in general payments reported to CMS, 2019-2025
57 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.59 · 2022: $1,106 · 2023: $1,262 · 2024: $1,407 · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,844 · Education: $83.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,844.24 |
| Education | $83.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $495.16 | 2022-2025 | Calquence, Enhertu, Imfinzi |
| Novartis Pharmaceuticals Corporation | $472.56 | 2022-2025 | |
| Janssen Biotech, INC. | $457.77 | 2022-2025 | Darzalex, Akeega, Erleada |
| Pfizer INC. | $248.51 | 2022-2025 | |
| Daiichi Sankyo INC. | $234.56 | 2021-2025 | Enhertu, Datroway |
| Seagen INC. | $207.62 | 2021-2023 | Padcev, Tukysa, Adcetris |
| E.R. Squibb & Sons, L.L.C. | $194.52 | 2021-2025 | Opdivo, Opdualag |
| Celgene Corporation | $182.09 | 2023-2024 | Reblozyl, Pomalyst, Opdualag |
| Pharmacyclics LLC, An Abbvie Company | $172.42 | 2021-2023 | Epkinly, Imbruvica |
| Glaxosmithkline, LLC. | $163.28 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $162.06 | 2023-2025 | Keytruda, Keytruda Qlex |
| Alexion Pharmaceuticals, INC. | $131.62 | 2022-2024 | Soliris, Ultomiris |
| Eisai INC. | $107.60 | 2022-2024 | |
| Incyte Corporation | $107.21 | 2022-2024 | Monjuvi, Pemazyre, Jakafi |
| Array Biopharma INC | $103.81 | 2022-2025 | Mektovi, Braftovi, Tukysa |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Kinzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.